Liraglutide-Induced Hepatotoxicity

A 52-year-old woman with a BMI of 31.2 kg/m(2) was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Maor, Yaakov, Ergaz, David, Malnick, Stephen D. H., Melzer, Ehud, Neuman, Manuela G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911918/
https://www.ncbi.nlm.nih.gov/pubmed/33498980
http://dx.doi.org/10.3390/biomedicines9020106
Descripción
Sumario:A 52-year-old woman with a BMI of 31.2 kg/m(2) was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug’s mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients.

Ejemplares similares